Down 8.2% on a down day: the S&P 500 is down 4.4% and 9 in 10 stocks are lower; health care stocks are down 5.2%; fertilizer stocks and telecom stocks rose.
Rose on Nov 4
Up 11% on Nov 4, a up day for the market: the S&P 500 rose 2%, 71% of stocks rose, and medical device stocks a median 7%.
OFIX's Quality Score fell 2 points on Thu, Nov 5, to -4.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Below its 200-day since January |
| Latest filing | 10-Q, Aug 5 |
TodayOn a down day.
After its last 4 reports it closed -6.2% on average, higher 1 of 4 times.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
OFIX is #79 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 79 |
Reports Mon Nov 9, before the open (in 4 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease was due to arbitration award and settlement payments related to pending claims from three former executives terminated in 2023.”
OFIX's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Net sales | $845M to $855M |
Sales grew 15% a year over 5 years, fiscal 2020 to 2025.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | +2.3% | -14.6% | -15.4% |
| May 5, 2026 | -0.2% | +3.6% | -2.8% |
| Feb 24, 2026 | -0.2% | -6.2% | -1.6% |
Sales grew in five of the last seven years, to $822M in 2025. It made a profit in two of the eight years.
3 insiders sold $5.8M across 7 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: OFIX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
“The global spine, biologics, limb reconstruction, and image guided surgery markets are highly competitive.”
OFIX scores -4 today, which Breakaway calls Poor. It is #79 of 85 in Medical Devices by Quality Score, with 1 of 14 chart checks firing. Up 11% on Nov 4, a up day for the market: the S&P 500 rose 2%, 71% of stocks rose, and medical device stocks a median 7%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
OFIX scores -4 today, which Breakaway calls Poor (below zero). That is #79 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OFIX's -4.
3 insiders sold $5.8M across 7 filings in the last 6 months. No open-market buys on record. The newest is Juniper Investment Company, LLC, 10% owner, who sold $1.7M on Sep 21. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.